Salutaris’ brachytherapy device earns FDA market clearance

The Food and Drug Administration recently granted Salutaris Medical Devices market clearance for its SMD-Sr90-DA Radionuclide Brachytherapy Source device.

Advertisement

The SMD-Sr90-DA RBS device is intended for episcleral brachytherapy — the treatment of a specific type of eye cancer. Brachytherapy is an advanced cancer treatment which entails placing radioactive implants in or near a tumor itself to deliver high radiation doses.

According to Tucson, Ariz.-based Salutaris Medical Devices, the tool was developed for use within a manual brachytherapy applicator system.

 

More articles on supply chain:

How payers can increase member engagement in 2017
SafeDose Scan device aims to reduce medication errors during acute emergency situations
How Target stores are functioning as mini distribution centers

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.